Innate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC Wainwright

Innate Pharma (NASDAQ:IPHA - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $11.50 price target on the stock. HC Wainwright's target price suggests a potential upside of 494.32% from the stock's previous close.

Innate Pharma Stock Performance

IPHA traded up $0.16 during trading on Friday, hitting $1.94. 9,500 shares of the company's stock were exchanged, compared to its average volume of 181,735. Innate Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $3.51. The business's 50 day moving average is $1.98 and its two-hundred day moving average is $1.93.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.